Solid Tumor, Adult
Conditions
Brief summary
This multicenter, open-label, first-in-human, Phase 1/2 study consists of a Part 1 (Phase 1) open-label dose escalation of EGL-001 administered as a single agent and in combination with an anti-PD(L)-1 treatment, followed by a Part 2 (Phase 2) open-label dose expansion of EGL-001 administered at the RP2D in patients with recurrent and/or metastatic solid tumors as monotherapy and/or combination therapy with anti-PD(L)-1.
Detailed description
In approximately 4 centers in France and 4 centers in Spain, 30 to 50 patients will be included in the dose escalation Part 1 of the trial. Number of participating countries and sites as well as patients will be defined based on Part 1 for Part 2 dose expansion phase.
Interventions
DRUGEGL-001
IV administration
Sponsors
Egle Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Dose escalation followed by combination therapy
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed written informed consent 2. Female or male patients, aged at least 18 years 3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 4. Life expectancy of at least 3 months as assessed by the investigator 5. Patients with confirmed locally advanced, unresectable, or metastatic solid tumors who have been previously treated with SoC and are no longer eligible for other therapies 6. Patients who have been treated with an ICI treatment as monotherapy or in combination as SoC 7. Have recovered from previous treatment 8. At least 1 measurable lesion according to RECIST Version 1.1 9. Adequate hematological, hepatic, and renal functions 10. Negative blood pregnancy test at screening for women of childbearing potential 11. Highly effective contraception during the study period and for 6 months after the last study treatment administration for WOCBP, and for male patients who are sexually active with WOCBP. Highly effective contraception methods are defined as: * Hormonal methods of contraception including combined oral contraceptive pills, vaginal ring, injectable, implants, intrauterine devices such as Mirena and nonhormonal intrauterine devices such as ParaGard for WOCBP patients or male patients' WOCBP partners * Tubal ligation * Vasectomy In addition to highly effective contraception, participating male patients: * Must use a condom during the study period and for 3 months after the last study treatment administration when engaging in any activity that allows for exposure to ejaculate * Must refrain from donating sperm 12. Must agree to abstain from donating blood while taking study drug and for 3 months following discontinuation of study treatment 13. Able to understand the character and individual consequences of clinical trial
Exclusion criteria
1. Patients with central nervous system metastases and/or leptomeningeal carcinomatosis with some exceptions 2. Patients with active or a documented history of autoimmune disease, immune deficiency or syndrome that required systemic corticoids (except the allowed dose) or immunosuppressive medications 3. Patients who received a previous ICI like anti-PD(L)-1 or an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to toxicity 4. Patients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs for a period of at least 4 weeks and whose treatment was not stopped 2 weeks prior to the first study treatment, with exceptions. Steroids with no or minimal systemic effect (topical, inhalation) are allowed 5. Patients with history of or current interstitial lung disease or fibrosis, and patients with pneumonitis 6. Other active malignancy requiring active intervention 7. Patients with previous malignancies other than the target malignancy to be investigated in this trial, unless a complete remission was achieved and no additional therapy is required during the study period 8. Patient with any organ transplantation, including allogeneic stem cell transplantation 9. Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma 10. Any known allergy or severe reaction to any component of anti-CTLA-4 or anti-PD(L)-1 drug product 11. Significant chronic or acute infections requiring systemic therapy including SARS-CoV-2 (COVID-19) PCR positive testing 12. Clinically significant active cardiovascular disease 13. Any other medical conditions or psychological disorders that would increase the safety risk to the patient or interfere with participation of the patient or the evaluation of the clinical study in the opinion of the investigator 14. Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety, tolerability, dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) leading to the recommended Phase 2 doses (RP2Ds) | Day 1 up to 90 days after last dose | DLTs occurrence per dose level of EGL-001 during the DLT period (number) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the preliminary antitumor efficacy (according to RECIST v1.1) | From Dose 1 to to the date of first documented tumor progression or death due to any cause, whichever occurs first. | ORR: the proportion of patients with complete response (CR) or partial response PR), based on local evaluations using RECIST Version 1.1. (%) |
Countries
France, Spain
Contacts
Primary ContactPejvack Motlagh, MD
Outcome results
None listed